Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases

[1] Dijkman GA(1996)Epidemiology of prostate cancer Eur Urol 30 281-295

[2] Debruyne FM(2000)Management of advanced prostate cancer Oncologist 5 36-44

[3] Auclerc G(1994)Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases J Nucl Med 35 63-69

[4] Antoine EC(1987)Skeletal localization of samarium-153 chelates: potential therapeutic bone agents J Nucl Med 28 495-504

[5] Cajfinger F(1998)Management of hormone-sensitive and hormone-refractory metastatic prostate cancer Cancer Control 5 513-521

[6] Brunet-Pommeyrol A(2007)Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer Eur J Nucl Med Mol Imaging 34 1023-1030

[7] Agazia C(2002)A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 1458-68

[8] Khayat D(2006)The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials Can J Urol 13 3180-3188

[9] Bayouth JE(2006)Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases Bone 39 35-41

[10] Macey DJ(1992)Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy J Nucl Med 33 748-750

[1] Dijkman GA(1996)Epidemiology of prostate cancer Eur Urol 30 281-295

[2] Debruyne FM(2000)Management of advanced prostate cancer Oncologist 5 36-44

[3] Auclerc G(1994)Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases J Nucl Med 35 63-69

[4] Antoine EC(1987)Skeletal localization of samarium-153 chelates: potential therapeutic bone agents J Nucl Med 28 495-504

[5] Cajfinger F(1998)Management of hormone-sensitive and hormone-refractory metastatic prostate cancer Cancer Control 5 513-521

[6] Brunet-Pommeyrol A(2007)Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer Eur J Nucl Med Mol Imaging 34 1023-1030

[7] Agazia C(2002)A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 1458-68

[8] Khayat D(2006)The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials Can J Urol 13 3180-3188

[9] Bayouth JE(2006)Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases Bone 39 35-41

[10] Macey DJ(1992)Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy J Nucl Med 33 748-750